ColoPlex PLUS

ColoPlex PLUS is a Multi-omic panel that combines protein and molecular biomarkers enhanced by ai software. 

DNA methylation of the SEPT9 and other tumor-associated genes is increased in colorectal cancer. The molecular biomarker, mSEPTIN 9can be measured in blood plasma using Real-Time PCR technology such as Applied Biosystems(R) 7500 Fast Dx Real-Time PCR Instrument.

Protein biomarkers are measured as a multiplex immunoassay using labeled microsphere bead technology on a Luminex IVD analyzer such as LX-200 or FlexMAP 3D.


ColoPlex™ PLUS provides patients and physicians with a simple, accurate blood testing option to detect colorectal cancer.

This early-detection blood test is aimed at driving the right people to confirmatory colonoscopy, reducing the overall costs of screening programs, and improving patient outcomes.

Convienient for Patients:

  • No messy fecal preparation. 
  • Can be part of your annual health check-up
  • Potential alternative screening method for those declining immunochemical test for occult blood. 

Colorectal Cancer Detection

  • ColoPlex PLUS data shows 90% specificity and 84% sensitivity.
  • CRC Cancer is the 3rd most diagnosed cancer
  • CRC is the 2nd leading cause of cancer death
  • CRC detected at Stage 1 has a 90% survival rate
  • A blood test will drive compliance with current screening recommendations. 


New Day Diagnostics’ research into cancer biomarkers identified numerous protein biomarkers which may be useful in the early detection of colorectal cancer and adenomas in patients. Utilizing multiplexing technology to measure all of these biomarkers in a single patient blood sample was the key to developing ColoPlex™ as an aid in diagnosis to help physicians identify potential candidates for colonoscopies.

ColoPlex™ can be added easily to the panel of tests routinely performed on the patient’s blood as part of the patient’s annual physical.  The results are as simple as the test itself, Positive or Negative. The result can help physicians identify patients who would benefit from additional diagnostics, including colonoscopies.



In the realm of life-saving tests, colonoscopies have proven their value in the fight to detect the presence of colorectal cancer. Yet, the cost, unpleasantness and discomfort caused by the test leads too many patients to avoid the procedure. In fact, only 50% of patients who should be screened have actually had a colonoscopy.

Whether avoiding the test because of a reluctance to experience discomfort, an unwillingness to take the time, or out of fear, this decision can cost a patient’s life. If detected at Stage I, colorectal cancer has a 90% five-year survival rate. By Stage II, the five-year rate drops to 60% and continues to fall to 10% at Stage IV. A colonoscopy is a valuable tool in detecting early stages of colorectal cancers, but it can’t work if the patient avoids testing.

Clearly a cost-effective alternative, such as a blood test, would be complimentary and drive the correct patients to colonoscopy, reducing false positives from current stool screening tests, and lowering healthcare costs.

New Day Diagnostics, a US-based medical company, asked this question and dove into extensive research to find a solution.


Coloplex®is a registered trademark of NewDay Diagnostics. ColoPlex is not FDA approved for sale in the U.S.A.